Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
about
Insig2 is associated with colon tumorigenesis and inhibits Bax-mediated apoptosisSW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profilingRole of nanotechnology and gene delivery systems in TRAIL-based therapiesAspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATMIs translational research compatible with preclinical publication strategies?Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway.Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.5-allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cellsNon-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsDihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.Colorectal carcinogenesis--update and perspectives.RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.Chemotherapeutic approaches for targeting cell death pathways.High cell surface death receptor expression determines type I versus type II signalingIsolation of a TRAIL antagonist from the serum of HIV-infected patients.Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine.TRAIL and its receptors as targets for cancer therapy.Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.TRAIL receptor-targeted therapy.Hydroxycamptothecin induces apoptosis and inhibits tumor growth in colon cancer by the downregulation of survivin and XIAP expressionThe promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.Combined modality therapy with TRAIL or agonistic death receptor antibodies.Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.Targeting Apoptotic Activity Against Prostate Cancer Stem Cells.Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway.Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells.A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs.Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5.Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin.Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells.Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAILA novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells.Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells.
P2860
Q24645231-2718D149-3BE0-443C-8C2C-64CBE9C4890BQ25255415-7CA83348-CDB1-41CD-A9A8-B5B1037C189AQ28076798-A6EC229B-2362-4ED3-A015-8BBB988B4A77Q28211000-32316056-DC3D-46F1-AC6C-CFAA1D841B8FQ30483105-70F33951-35B3-4C27-A9E6-041F64104880Q33207662-41C7F89B-3486-4C7F-BF8B-66CF7428143AQ33680928-EA0B6D82-A2D9-456A-B33C-6DDDFC26392FQ33947014-E05A90C0-3EBE-4C2D-BE68-F1446F09E90AQ33975484-37443832-1DBB-417E-9BEE-728A104A7736Q34002666-DFE737FE-EF02-45CD-986A-1CAB3C61B416Q34008793-1FF027A4-3638-4DF6-819E-3685016A3DFAQ34292461-801976CA-2FD3-4986-A57A-576FEEB490FAQ34564468-16A318B0-0B9F-4007-B990-213D3348BF6BQ34667352-FB1058D1-AE89-456F-AB86-4C0732601F24Q35010521-27BBBD85-6F16-4EA6-8E38-CFBCD4B7D910Q35094229-FC1855AF-9FF5-4B23-8195-70BF4E69BC44Q35371553-9BE26C54-031F-4D4D-9C24-A11F83C05315Q35372514-1D8EC32A-99AA-4ADC-A070-7333B625DDF2Q35600313-2481BA7C-E5FF-4D28-B7C9-756FA2122BCBQ35927476-4E157A32-B119-4AF1-ADA8-A678C5EFC48EQ35951059-787060CA-A21D-491F-A498-5FCB357EDB83Q36365504-46D5A832-14EA-442E-850D-29E5131916FCQ36572530-400DF21A-FA06-4BBF-94BC-69AD1607A6CBQ36921799-A23732D7-0697-4865-96F4-BE289003C40DQ37302737-D742F365-10F0-46BC-BBAE-CB9C2BA943DEQ37832083-F3951DE0-E7E7-4AC6-BA20-DC62C5A6A06FQ38557486-68E88F34-9D83-44D9-89E5-9BAE9E480524Q38652074-0D3CEAC5-E708-46B3-8813-3FB47638A498Q39248620-2459F61E-EEBD-42A6-8BE8-34ACCA341E2EQ39300613-C65088D4-9B69-44DA-ACC9-2E1F09A8E138Q39472164-060AF4F4-B2A2-40AE-B659-8F4243C61192Q39595777-BB36562F-4B54-4211-9CFE-7627451C6A58Q39706496-B25A83D4-9C2D-4085-966E-F0F165791AF4Q39852248-5F079080-885E-48CB-B781-715B88D169B2Q39935218-386001ED-3A68-48C2-A217-788D2CA87284Q39958722-5C913B62-860E-43A7-8FCA-071481838D81Q40023794-620CE016-6D61-4644-9037-DB08BC93BA85Q40105893-A4AB37E5-E31E-4CB9-AD94-0C43A3BA0A50Q40486081-170281C8-6037-485A-874D-9ECBDE9D1427Q40540390-F049CD6A-5698-4C89-96BC-414A221C0354
P2860
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Requirement of p53 targets in ...... inoma to death ligand therapy.
@ast
Requirement of p53 targets in ...... inoma to death ligand therapy.
@en
Requirement of p53 targets in ...... inoma to death ligand therapy.
@nl
type
label
Requirement of p53 targets in ...... inoma to death ligand therapy.
@ast
Requirement of p53 targets in ...... inoma to death ligand therapy.
@en
Requirement of p53 targets in ...... inoma to death ligand therapy.
@nl
prefLabel
Requirement of p53 targets in ...... inoma to death ligand therapy.
@ast
Requirement of p53 targets in ...... inoma to death ligand therapy.
@en
Requirement of p53 targets in ...... inoma to death ligand therapy.
@nl
P2860
P356
P1476
Requirement of p53 targets in ...... cinoma to death ligand therapy
@en
P2093
Shulin Wang
P2860
P304
15095-15100
P356
10.1073/PNAS.2435285100
P407
P577
2003-11-26T00:00:00Z